Introduction
============

Pancreatic cancer (PC) is the seventh most common cause of cancer mortality and causes 330,000 deaths per year worldwide, accounting for approximately 4.0% of all cases of cancer.[@b1-ott-10-3991] Currently, while the incidence of PC tends to linearly increase, the mortality of PC is high, and the prognosis is dismal. It is estimated that patients who present with early disease and have a negative resection margin only have a 5-year survival rate of 24%.[@b2-ott-10-3991] There is an even higher mortality for unresectable patients. Currently, PC lacks a sensitive diagnosis marker to monitor the disease at an early stage and to predict the prognosis. Therefore, PC is in desperate need of a new index.

Long noncoding RNAs (lncRNAs) do not encode proteins and were once regarded as transcriptional noise or cloning artifacts.[@b3-ott-10-3991],[@b4-ott-10-3991] According to recent research, lncRNAs are thought to be regulators of cancer development, which make them a promising target for cancer treatment.[@b5-ott-10-3991],[@b6-ott-10-3991] MALAT1, with a length of over 8,000 nucleotides, is a highly conserved lncRNA that is derived from chromosome 11q13. It controls cancer cell proliferation, differentiation, apoptosis, and invasion by regulating the synthesis of proteins and the expression of genes. MALAT1 is well known as the first lncRNA, indicating the poor prognosis of non-small-cell lung cancer.[@b7-ott-10-3991] Currently, emerging research has shown that MALAT1 plays a crucial role in ovarian cancer,[@b8-ott-10-3991] esophageal cancer,[@b9-ott-10-3991] prostate cancer[@b10-ott-10-3991] breast cancer,[@b11-ott-10-3991] thyroid cancer,[@b12-ott-10-3991] nasopharyngeal carcinoma,[@b13-ott-10-3991] and other types of malignant diseases. Previously, studies have found that elevated MALAT1 levels are involved in PC proliferation and metastasis through the stimulation of autophagy.[@b14-ott-10-3991] Nevertheless, the potential molecular mechanism is still unclear and needs additional research. Over the last few years, there have been numerous novel techniques related to cancer mechanism and therapy exploration emerging. For instance, molecular docking and molecular dynamics simulation, which helps identify the cancer-associated single nucleotide polymorphisms and their possible molecular mechanism.[@b15-ott-10-3991]--[@b17-ott-10-3991] And other analysis including protein--ligand interaction analysis, principal component analysis, shape analysis of binding pocket, and kinase inhibitor screening are also used to explore the therapeutic molecules for cancers.[@b18-ott-10-3991],[@b19-ott-10-3991] Researchers are also trying to figure out a methodology to optimize a synergistic and clinically achievable combination of multiple agents for cancer clinical therapy.[@b20-ott-10-3991] Despite their particular perspectives in uncovering the cancer mechanism and therapy, the complicated and demanding operation of the experimental techniques themselves might limit their further development. As a result, we hope to use computational methods to explore the cancer mechanism by virtue of online databases. Thus, in this paper, we performed a comprehensive study to further explore the clinical significance and underlying molecular mechanism of MALAT1 in PC on a computational level.

To explore the relationship between MALAT1 and PC, we collected gene expression data and clinical data from patients using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The relationship between MALAT1 and PC was further analyzed based on the TCGA and GEO data. For the purpose of exploring the molecular mechanism, we analyzed the overlapping genes in the differentially expressed genes after MALAT1 knockout and the coexpressed genes from TCGA. We performed a bioinformatics functional analysis for the overlapping genes and used Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Protein--Protein Interaction (PPI) databases.

Taken together, we hope to understand the clinical value of MALAT1 in PC and the molecular mechanism of MALAT1. We hope that the data shown here may offer new perspectives in future research and clinical application.

Materials and methods
=====================

Selection of microarrays in GEO datasets and profiles
-----------------------------------------------------

For the purpose of understanding the diagnostic value of MALAT1 in PC, we systematically retrieved the GEO microarrays performed before December 2016 for a meta-analysis. The retrieval strategies were as follows: Pancrea\* AND (adenocarcinoma OR carcinoma OR cancer OR neoplasm OR tumor OR tumour OR neoplas\* OR malignan\*). The inclusion criteria were as follows: 1) the enrolled subjects included patients with PC and normal control samples, 2) MALAT1 was expressed, detected, and available for extraction in the enrolled subjects, and 3) there were more than three subjects.

Validation of MALAT1 expression in PC based on the Oncomine database
--------------------------------------------------------------------

The Oncomine database (<http://www.oncomine.org>) incorporates 264 independent datasets that include 35 cancer types and supports various methods of analysis, including molecular concepts analysis, interactome analysis, and meta-analysis.[@b21-ott-10-3991] Thus, we adopted the Oncomine database to further validate the expression of MALAT1 in PC. The differential expression analysis was directly performed using Oncomine online analysis tools.

Identification of the clinical prognostic value of MALAT1 in PC
---------------------------------------------------------------

TCGA (<http://cancergenome.nih.gov>) data portal is one of the largest available public resources offering genomic, transcriptomic, methylomic, and copy number variation datasets for more than 20 cancer types.[@b22-ott-10-3991],[@b23-ott-10-3991] We evaluated the TCGA survival of patients with PC in two online analysis websites, cBioPortal for Cancer Genomics[@b24-ott-10-3991],[@b25-ott-10-3991] (<http://www.cbioportal.org/>) and OncoLnc[@b26-ott-10-3991] (<http://www.oncolnc.org/>), which link to the TCGA database.

Identification of key differentially expressed genes associated with MALAT1 in PC
---------------------------------------------------------------------------------

For the purpose of investigating the genes influenced by MALAT1, we performed GeneChip analysis after MALAT1 was knocked down. The human PC Miapaca-2 cell line was purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Wuhan, People's Republic of China), and was maintained routinely in Dulbecco's Modified Eagle's Medium (Thermo Fisher Scientific, Waltham, MA, USA). The four siRNAs for MALAT1 were designed on the internet (<http://design.RNAi.jp/>) and synthesized by Shanghai Jima company. Lentivirus MALAT1-shRNA was synthesized using lentivirus, packaged, and screened. The knockdown rate of MALAT1-stable cells was 76% in Miapaca-2 cell line with the best siRNA sequence (F:GGCAGCTTTAACAGATAACA; R:CCGTCCGACAAGGGTCATTCA). The three groups of control vector cells and MALAT1-shRNA stable cells were tested with GeneChip prime view human kit (Affymetrix., 901838, Santa Clara, CA, USA). Using MALAT1 knockdowns, we first acquired the differentially expressed genes. After performing GO analysis, we obtained the enriched GO data and the corresponding genes. Furthermore, we collected MALAT1 and mRNA gene coexpression data from the TCGA database. We adopted 0.15 as the cut-off value for screening the significant coexpression genes. Aiming at determining the most likely key differentially expressed MALAT1-associated genes in PC, we further correlated the enriched GO items with correlative genes and TCGA coex-pression genes. The overlapping genes we obtained were used for further analysis.

Bioinformatics analysis of the overlapping genes
------------------------------------------------

For the overlapping genes, The Database for Annotation, Visualization, and Integrated Discovery version 6.7 (<https://david-d.ncifcrf.gov/>), an online bioinformatics functional enrichment resource for a list of genes analysis,[@b27-ott-10-3991],[@b28-ott-10-3991] was used to perform GO enrichment and KEGG pathway analysis. The analysis was achieved via uploading the overlapping genes though the Functional Annotation porch. We chose those items whose *P*-values were below 0.05 for further study. Further, we used BiNGO, a plugin of Cytoscape 3.40,[@b29-ott-10-3991] to visualize the GO enrichment pathway, which includes biological process (BP), cellular component (CC), and molecular function (MF). Meanwhile, we also aimed to identify the most crucial target genes of MALAT1 from the overlapping genes. The STRING database version 10 (<http://string-db.org/>) is aimed at providing a critical assessment and integration of PPI through direct (physical) and indirect (functional) associations network construction.[@b30-ott-10-3991] Thus, STRING database was further used to perform a protein--protein interaction network analysis. The PPI network construction was achieved through StringApp, a plugin of Cytoscape 3.40, which links to STRING database. Interaction score (0.7) was adopted as a high confidence cut-off value to determine the PPI. Hub genes, which are the key genes in PC, were obtained from the network.

Statistical analysis
--------------------

Stata 12.0 (Stata Corp., College Station, TX, USA) was used to perform a GEO microarray meta-analysis in this study. Receiver operating characteristic (ROC) curve analyses were utilized to evaluate the diagnostic value of MALAT1 in PC and normal tissue. Kaplan--Meier curves and the log-rank test were applied to analyze the effect of MALAT1 on the survival outcome of patients with PC. Only *P*\<0.05 was considered statistically significant.

Results
=======

Characteristics of the included datasets
----------------------------------------

A total of 27 eligible datasets published from 2008 to 2016 in the GEO database were used in this study. The characteristics of the selected datasets are shown in [Table 1](#t1-ott-10-3991){ref-type="table"}. In total, 764 PC samples and 469 healthy controls were used.

Clinical diagnostic value of MALAT1 as a biomarker in PC based on the GEO datasets
----------------------------------------------------------------------------------

After pooling the data from the 27 eligible datasets, we found that there was significant heterogeneity among the datasets (*I*^2^=61.1%, *P*=0.000, [Figure 1](#f1-ott-10-3991){ref-type="fig"}). As a result, we performed a sensitivity analysis to screen the possible data-sets that might cause the heterogeneity. As can be seen in [Figure 2](#f2-ott-10-3991){ref-type="fig"}, two datasets, namely, GSE15471 and GSE62165, may contribute to significant heterogeneity. Thereby, we removed the two datasets and recalculated the pooled standard mean difference. As shown in [Figure 3](#f3-ott-10-3991){ref-type="fig"}, the heterogeneity appears to have disappeared (*I*^2^=44.9%, *P*=0.009). The pooled standard mean difference was 0.23 (95% confidence interval \[CI\]: 0.10--0.37, *P*=0.001), which indicates a significant difference in the effect of MALAT1 between patients with PC and healthy control patients. The expression of MALAT1 was significantly upregulated. Publication bias among the 25 datasets was assessed through Begg's funnel plot. As shown in [Figure 4](#f4-ott-10-3991){ref-type="fig"}, the funnel plot was basically considered symmetrical. Taking *P*\>0.05 as cut-off value, we found that *P*=0.414 was obtained by Begg's test, which indicated that no significant publication bias existed. Furthermore, a summary ROC curve revealed that the area under the curve was 0.75 (95% CI: 0.71--0.78), and the overall sensitivity and specificity was 0.66 (95% CI: 0.57--0.74) and 0.72 (95% CI: 0.61--0.81) ([Figures 5](#f5-ott-10-3991){ref-type="fig"} and [6A](#f6-ott-10-3991){ref-type="fig"}). The pooled diagnostic odds ratio was also calculated as 4.41 (95% CI: 2.71--7.17), which indicates that upregulated MALAT1 results in a higher risk of PC ([Figure 6B](#f6-ott-10-3991){ref-type="fig"}).

MALAT1 expression difference validation based on the Oncomine database
----------------------------------------------------------------------

Five PC datasets in the Oncomine database were adopted for the validation of MALAT1 expression (Grutzmann's dataset \[<http://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-950>\]; Badea's datasets \[<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15471>\]; lacobuzio-Donahue's dataset \[<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3654>; <http://genome-www.stanford.edu/pancreatic1/index.shtml>\]; Pie's dataset \[<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16515>\]; Ishikawa's dataset \[<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1542>\]). In Grutzmann's and Badea's datasets, the expression of MALAT1 was significantly elevated in PC, which was in accordance with the results of the meta-analysis ([Figure 7A and B](#f7-ott-10-3991){ref-type="fig"}). The *P*-values for these datasets were 0.025 and \<0.01, respectively. However, the remaining three datasets did not show a statistically significant difference in MALAT1 expression ([Figure 7C--E](#f7-ott-10-3991){ref-type="fig"}).

Prognostic value of MALAT1 based on the TCGA database
-----------------------------------------------------

For the analysis using the cBioPortal for Cancer Genomics, the survival data for a total of 178 PC patients was analyzed. We found 10 of 178 patients had alterations in the expression of MALAT1 (Supplementary material 1). Thus, we evaluated the survival of the cases with MALAT1 alteration compared to those without MALAT1 alteration. The log-rank test showed that the *P*-value was 0.0380 ([Figure 8A](#f8-ott-10-3991){ref-type="fig"}). As reported on the Oncolnc website, we analyzed the survival of patients with high MALAT1 expression and compared it to that of patients with low MALAT1 expression in a total of 174 patients with PC. It showed a trend that high MALAT1 expression indicates better survival, although no statistical significance was observed (*P*=0.304, [Figure 8B](#f8-ott-10-3991){ref-type="fig"}).

Collection of the overlapping genes
-----------------------------------

After knocking down MALAT1, we performed a GO enrichment analysis and collected 656 enriched GO gene symbols. Furthermore, using 0.15 as *P*-value cut-off, we obtained 5,887 coexpressed genes from the TCGA database. We then intersected the two part genes and gathered 224 overlapping genes (Supplementary material 2), which might become the crucial targets genes of MALAT1 in PC.

Bioinformatics analysis of the overlapping genes
------------------------------------------------

As displayed in [Table 2](#t2-ott-10-3991){ref-type="table"}, the overlapping genes contain three enriched GO pathway categories: BP, CC, and MF. In the BP category, the enriched items were mainly intracellular transport, regulation of phosphorus metabolic process, regulation of phosphate process, etc. In the CC category, membrane-enclosed lumen, nuclear lumen, and nuclear chromosome, among others, were the main components of the enrichment. In regards to the MF category, protein dimerization activity, nucleoside binding, and purine nucleoside binding ranked as the top three enriched items. All of the enriched GO pathways, including the BP, CC, and MF categories, were further visualized through Cytoscape 3.40 and the results are displayed in Supplementary materials 3 and 4 and [Figure 9](#f9-ott-10-3991){ref-type="fig"}, respectively. In the KEGG pathway analysis, we identified the mTOR signaling pathway, pathways in cancer, and the MAPK signaling pathway as the top three enriched pathways ([Table 2](#t2-ott-10-3991){ref-type="table"}). Interestingly, we also found that the PC pathway was one of the significantly enriched pathways. Five target genes (*VEGFC*, *CCND1*, *PIK3CB*, *VEGFA*, and *MAPK8*) were involved in the PC pathway. A PPI was constructed (Supplementary material 5) and six hub genes (*CCND1*, *MAPK8*, *VEGFA*, *FOS*, *CDH1*, and *HSP90AA1*) were identified ([Figure 10](#f10-ott-10-3991){ref-type="fig"}).

Discussion
==========

In this paper, we first discovered that the expression of MALAT1 was significantly upregulated in PC patients by using a meta-analysis of 27 published GEO microarrays, which included a total of 764 patients with PC and 469 healthy controls. Further validation via the Oncomine database was consistent with the GEO microarray meta-analysis. Using the TCGA database, we acquired the survival data of the patients and investigated the influence of the alteration of MALAT1 expression on the patients' prognosis. Furthermore, using our own GeneChip and TCGA database, we collected and intersected the enriched GO genes after knocking down MALAT1 and the coexpressed genes in TCGA. Further bioinformatics analysis of the overlapping genes, which aims to explore the underlying molecular regulatory mechanism, was performed.

During the past few years, alteration of MALAT1 has been found to be involved in malignancies and other diseases. Shuai et al[@b31-ott-10-3991] performed a meta-analysis that revealed that MALAT1 served as a promising biomarker for the prognosis of numerous malignancies, including digestive system cancers, urinary system cancers, and respiratory system cancers. In our study, we observed upregulated MALAT1, which is consistent with other previous reports, such as those by Li et al,[@b14-ott-10-3991] Pang et al,[@b32-ott-10-3991] and Liu et al.[@b33-ott-10-3991] Elevated MALAT1 has also been reported in gastric cancer,[@b34-ott-10-3991] hepatocellular carcinoma,[@b35-ott-10-3991] gallbladder cancer,[@b36-ott-10-3991] esophageal cancer,[@b37-ott-10-3991] and clear cell renal cell carcinoma.[@b38-ott-10-3991] Considering all of the above information, MALAT1 appears to play a distinct role in different tumors, which provides a brand new perspective for future cancer therapy.

In the present study, we discovered that MALAT1 showed a moderate performance in diagnosing PC after meta-analysis of a large number of PC, and corresponding control, samples. The area under the curve for the summary ROC curve was 0.75, with a sensitivity of 0.66 and a specificity of 0.72. Thus far in the published literature, there is no report evaluating the diagnostic value of MALAT1 in PC through comprehensive meta-analysis. As a consequence, the information in this study will provide a valuable reference for clinical PC diagnosis. To date, several studies have reported that higher MALAT1 expression suggests poorer survival.[@b31-ott-10-3991],[@b32-ott-10-3991] Regarding our results, we found that patients with MALAT1 alteration had better survival than patients without MALAT1 alteration (*P*=0.0380). We also found that the high expression of MALAT1 suggested better survival in the Kaplan--Meier curves. However, the *P*-values did not show statistical significance. Therefore, the exact prognostic value of MALAT1 in PC still remains unknown.

Since lncRNAs exert their regulatory function by specifically binding with target genes, we also aimed to determine possible targets of MALAT1 and to further explore the possible molecular pathways. Through a GO enrichment analysis, some top-ranked GO items, such as intracellular transport, membrane-enclosed lumen, and protein dimerization activity, were found to be possible crucial events in PC development. Regarding the KEGG pathway analysis, several significant pathways, such as the mTOR signaling pathway, pathways in cancer, and the MAPK signaling pathway, were discovered. Importantly, the PC pathway was also one of the enriched KEGG pathways. Five genes, *VEGFC*, *CCND1*, *PIK3CB*, *VEGFA*, and *MAPK8*, are target genes of MALAT1, which might also be key target genes in PC. Interestingly, according to previous studies, we found that the mTOR signaling pathway has been reported to be involved in PC.[@b39-ott-10-3991],[@b40-ott-10-3991] Additionally, the MAPK signaling pathway also has been reported to play a role in PC.[@b41-ott-10-3991] Therefore, to some extent, the pathways identified here might provide more evidence for elucidating the potential molecular mechanism in PC. Finally, the PPI network suggests that six hub genes (*CCND1*, *MAPK8*, *VEGFA*, *FOS*, *CDH1*, and *HSP90AA1*) might serve as pivotal target genes of MALAT1 in PC. We discovered that *CCND1*, *MAPK8*, and *VEGFA* also participate in the PC pathway, as mentioned. As a consequence, we concentrate on the top three genes (*CCND1*, *MAPK8*, and *VEGFA*), which may be important genes, for detailed discussion.

CCND1, also known as BCL1, encodes a highly conserved cyclin protein, which exerts regulatory functions on CDK kinases. Mutation, amplification, and overexpression of CCND1 alter cell cycle progression, which might contribute to tumorigenesis. As a result, CCND1 alteration was frequently discovered in various tumors. The CCND1 genotype has been reported to be related to the risk for various cancers, such as colorectal cancer,[@b42-ott-10-3991] acute lymphoblastic leukemia,[@b43-ott-10-3991] glioma,[@b44-ott-10-3991] esophageal squamous cell carcinoma,[@b45-ott-10-3991] gastric cancer,[@b46-ott-10-3991] and nasopharyngeal carcinoma.[@b47-ott-10-3991],[@b48-ott-10-3991] Moreover, CCND1 was also reported to play different roles in cancer survival, such as in lung adenocarcinoma,[@b49-ott-10-3991],[@b50-ott-10-3991] prostate cancer,[@b51-ott-10-3991] meningioma[@b52-ott-10-3991] gastric adenocarcinoma,[@b53-ott-10-3991] and colorectal cancer.[@b54-ott-10-3991] In regards to PC, Deharvengt et al[@b55-ott-10-3991] reported that CCND1 is a target of a B lentivirus-delivered shRNA, which exerts suppressive effects on the growth, invasiveness, tumorigenicity, and proangiogenic potential of PC. Another study found that CCND1 was a strong prognostic biomarker for PC survival.[@b56-ott-10-3991] Taken together, it is obvious that CCND1 is involved in various cancers, including PC. However, whether it is related to MALAT1 has not been reported to date, and further studies are required.

MAPK8, also named JNK or JNK1, belongs to the MAPK kinase family that acts as an integration point in numerous cellular processes, such as proliferation, differentiation, transcription regulation, and development. Increasing amounts of evidence have proven that MAPK8 has a crucial role in a wide variety of cancers. Chang et al[@b57-ott-10-3991] discovered that JNK1 activation was capable of predicting poor prognosis in hepatocellular carcinoma. Moreover, Okada et al[@b58-ott-10-3991] reported that JNK can inhibit temozolomide, thus acting as a rational therapeutic biomarker in glioblastoma. JNK activity has also been reported in endometrial cancer,[@b59-ott-10-3991] melanoma,[@b60-ott-10-3991] colon cancer,[@b61-ott-10-3991] etc. In regard to PC, Sahu et al[@b62-ott-10-3991] reported that JNK was involved in benzyl isothiocyanate (BITC)-mediated G(2)/M arrest to mediate apoptosis in human PC cells. Another study also found that JNK1 is activated by Irofulven treatment, which induces apoptosis in human PC cells.[@b63-ott-10-3991] Therefore, based on the abovementioned information, MAPK8 could possibly serve as a target gene of MALAT1 in PC, but additional studies are needed.

VEGFA, also known as VPF, VEGF, and MVCD1, is a member of the PDGF/VEGF growth factor family. Encoding a heparin-binding protein, it induces the proliferation and migration of vascular endothelial cells, which is fundamental for physiological and pathological angiogenesis. Upregulated VEGFA is common in many tumors and is related to tumor stage and progression. Liu et al[@b64-ott-10-3991] reported that VEGFA polymorphisms might play a potential role in the development and clinical outcome of hepatocellular carcinoma. VEGFA has also been found to be inhibited by miR-1, which exerts inhibitory functions in osteosarcoma cells, as well as promotes proliferation, migration, and invasion.[@b65-ott-10-3991] Furthermore, Zeng et al[@b66-ott-10-3991] found that downregulation of VEGFA can inhibit proliferation, migration, and invasion and can promote apoptosis in renal clear cell carcinoma. VEGFA in tumors has also been studied in breast cancer,[@b67-ott-10-3991],[@b68-ott-10-3991] laryngeal carcinoma,[@b69-ott-10-3991] colorectal cancer,[@b70-ott-10-3991],[@b71-ott-10-3991] bladder cancer,[@b72-ott-10-3991] and lung cancer.[@b73-ott-10-3991] In PC, Liu et al[@b74-ott-10-3991] found that VEGFA was involved in the Twist/miR-497/VEGFA axis, which is significantly correlated to metastasis and angiogenesis in PC. VEGFA secretion has also been reported to be regulated by myoferlin and affects tumor-associated angiogenesis in PC.[@b75-ott-10-3991] In summary, as VEGFA has been shown to be important in cancers, it is suggested that VEGFA is a target of MALAT1 in PC. However, more studies are needed.

There are limitations in this study. Here, we have attempted to explore the relationship between MALAT1 and PC clinical parameters based on the TCGA database. However, no statistical significance was observed. Therefore, it still remains to be seen if there is a correlation between MALAT1 and PC. In addition, in this study, the exploration occurred at a bioinformatics level. Further experiments are needed to validate these assumptions.

In sum, we discovered that upregulated MALAT1 acts as a biomarker for the diagnosis of PC. The alteration or upregulation of MALAT1 expression tends to predict better prognostic outcome in PC. Several pathways, such as the mTOR signaling pathway, pathways in cancer, and the MAPK signaling pathway, might be targeted by MALAT1 and participate in the PC process. Six hub genes (*CCND1*, *MAPK8*, *VEGFA*, *FOS*, *CDH1*, and *HSP90AA1*), and specifically *CCND1*, *MAPK8* and *VEGFA*, were identified as key target genes of MALAT1 in PC. Here, we provided clinical reference values and underlying molecular mechanisms for MALAT1 in PC. These findings still need to be validated in future studies.

Conclusion
==========

MALAT1 seems to act as a promising diagnostic biomarker in PC. Six hub genes (*CCND1*, *MAPK8*, *VEGFA*, *FOS*, *CDH1*, and *HSP90AA1*), specifically *CCND1*, *MAPK8*, and *VEGFA*, might be key correlative genes of MALAT1 in PC. Several pathways related to MALAT1, such as the mTOR signaling pathway, pathways in cancer, and the MAPK signaling pathway may play a crucial role in PC. The information we have obtained might shed light on clinical application and future research. Nevertheless, more experimental studies are needed to further validate these findings.
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![Forest plot of 27 GEO datasets evaluating the SMD of MALAT1 in the PC group and the healthy control group (a fixed-effect model).\
**Abbreviations:** CI, confidence interval; GEO, Gene Expression Omnibus; PC, pancreatic cancer; SMD, standard mean difference.](ott-10-3991Fig1){#f1-ott-10-3991}

![Sensitivity analysis to evaluate the heterogeneity among 27 GEO datasets.\
**Note:** The results were computed by omitting each dataset in turn.\
**Abbreviations:** CI, confidence interval; GEO, Gene Expression Omnibus.](ott-10-3991Fig2){#f2-ott-10-3991}

![Forest plot of 25 GEO datasets evaluating the SMD of MALAT1 in the PC group and the healthy control group after omitting two datasets (GSE15471 and GSE62165) (a fixed-effect model).\
**Abbreviations:** CI, confidence interval; GEO, Gene Expression Omnibus; PC, pancreatic cancer; SMD, standard mean difference.](ott-10-3991Fig3){#f3-ott-10-3991}

![Begg's funnel plot evaluating the publication bias among the 25 datasets.\
**Abbreviations:** CI, confidence interval; SE, standard error; SMD, standard mean difference.](ott-10-3991Fig4){#f4-ott-10-3991}

![Summary of the ROC curve of 25 datasets evaluating the diagnostic value of MALAT1 in PC.\
**Abbreviations:** AUC, area under the curve; CI, confidence interval; PC, pancreatic cancer; ROC, receiver operating characteristic; SENS, sensitivity; SPEC, specificity; SROC, summary receiver operating characteristic.](ott-10-3991Fig5){#f5-ott-10-3991}

###### 

Forest plot of 25 datasets evaluating the diagnostic value of MALAT1 in PC.

**Notes:** (**A**) Pooled sensitivity and specificity of 25 datasets. (**B**) Pooled diagnostic OR of 25 datasets.

**Abbreviations:** OR, odds ratio; PC, pancreatic cancer.
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###### 

Box plot validating the expression of MALAT1 in the PC group and the healthy control group based on the Oncomine database.

**Notes:** (**A**) The expression of MALAT1 in Grutzmann's dataset (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-950>). (**B**) The expression of MALAT1 in Badea's datasets (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15471>). (**C**) The expression of MALAT1 in lacobuzio-Donahue's dataset (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3654>; <http://genome-www.stanford.edu/pancreatic1/index.shtml>). (**D**) The expression of MALAT1 in Pie's dataset (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16515>). (**E**) The expression of MALAT1 in Ishikawa's dataset (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1542>).

**Abbreviation:** PC, pancreatic cancer.
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###### 

Survival analysis evaluating the prognostic value of MALAT1 in PC.

**Notes:** (**A**) Patients with PC were divided into two groups according to MALAT1 alteration. (**B**) Patients with PC were divided into two groups according to MALAT1 expression.

**Abbreviation:** PC, pancreatic cancer.
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![Significant MF network constructed by Cytoscape 3.40.\
**Notes:** Each node represents a GO item. Colored nodes indicate significance (*P*\<0.01). Node size represents the involved MF items.\
**Abbreviations:** GO, Gene Ontology; MF, molecular function.](ott-10-3991Fig9){#f9-ott-10-3991}

![Hub genes obtained from the PPI network.\
**Note:** A degree ≥10 was chosen as the cut-off point.\
**Abbreviation:** PPI, protein--protein interaction.](ott-10-3991Fig10){#f10-ott-10-3991}

###### 

Characteristics of the GEO datasets included in the meta-analysis

  Series     Country                      Year   Platform      Sample source             PC patients   Normal tissues
  ---------- ---------------------------- ------ ------------- ------------------------- ------------- ----------------
  GSE14245   USA                          2008   GPL570        Saliva                    12            12
  GSE11838   USA                          2008   GPL6977       Tissue                    28            79
  GSE15471   Romania                      2009   GPL570        Tissue                    39            39
  GSE16515   USA                          2009   GPL570        Tissue                    36            16
  GSE22780   USA                          2011   GPL570        Tissue                    8             8
  GSE32676   USA                          2011   GPL570        Tissue                    25            7
  GSE18670   Belgium                      2012   GPL570        Tissue/peripheral blood   6             6
  GSE15932   People's Republic of China   2012   GPL570        Peripheral blood          16            8
  GSE28735   USA                          2012   GPL6244       Tissue                    45            45
  GSE23397   Germany                      2013   GPL5188       Tissue                    15            6
  GSE41368   Italy                        2013   GPL6244       Tissue                    6             6
  GSE43795   South Korea                  2013   GPL10558      Tissue                    26            5
  GSE49641   Spain                        2013   GPL6244       Peripheral blood          18            18
  GSE43288   UK                           2013   GPL96/GPL97   Tissue                    4             3
  GSE27890   USA                          2014   GPL570        Tissue                    4             4
  GSE56560   UK                           2014   GPL5175       Tissue                    28            7
  GSE58561   Norway                       2014   GPL14550      Tissue                    3             2
  GSE55643   UK                           2014   GPL6480       Tissue                    45            8
  GSE60979   Norway                       2015   GPL14550      Tissue                    49            12
  GSE71008   USA                          2015   GPL9052       Plasma                    6             50
  GSE74629   Spain                        2015   GPL10558      Peripheral blood          36            14
  GSE71989   USA                          2015   GPL570        Tissue                    14            8
  GSE62165   Belgium                      2016   GPL13667      Tissue                    118           13
  GSE62452   USA                          2016   GPL6244       Tissue                    69            61
  GSE86436   People's Republic of China   2016   GPL13825      Tissue                    6             6
  GSE77858   USA                          2016   GPL7264       Tissue                    77            3
  GSE91035   USA                          2016   GPL22763      Tissue                    25            23

**Abbreviations:** GEO, Gene Expression Omnibus; PC, pancreatic cancer.

###### 

Significant GO and KEGG items of the overlapping genes

  Category        Term                                                      Count   *P*-value   Benjamini   FDR
  --------------- --------------------------------------------------------- ------- ----------- ----------- ----------
  GOTERM_BP_FAT   GO:0046907\~intracellular transport                       26      2.06E-05    0.032809    0.034527
  GOTERM_BP_FAT   GO:0051174\~regulation of phosphorus metabolic process    21      4.84E-05    0.038433    0.081107
  GOTERM_BP_FAT   GO:0019220\~regulation of phosphate metabolic process     21      4.84E-05    0.038433    0.081107
  GOTERM_BP_FAT   GO:0042325\~regulation of phosphorylation                 20      8.74E-05    0.046107    0.146486
  GOTERM_BP_FAT   GO:0042127\~regulation of cell proliferation              26      0.000361    0.136005    0.603502
  GOTERM_BP_FAT   GO:0045859\~regulation of protein kinase activity         15      0.000791    0.226216    1.318661
  GOTERM_BP_FAT   GO:0006915\~apoptosis                                     21      0.00083     0.200893    1.383248
  GOTERM_BP_FAT   GO:0012501\~programmed cell death                         21      0.000996    0.205897    1.656699
  GOTERM_BP_FAT   GO:0043549\~regulation of kinase activity                 15      0.001101    0.199873    1.829703
  GOTERM_BP_FAT   GO:0006468\~protein amino acid phosphorylation            22      0.001215    0.196549    2.01821
  GOTERM_CC_FAT   GO:0031974\~membrane-enclosed lumen                       43      0.000252    0.073845    0.337322
  GOTERM_CC_FAT   GO:0031981\~nuclear lumen                                 36      0.000284    0.042315    0.380158
  GOTERM_CC_FAT   GO:0000228\~nuclear chromosome                            10      0.000299    0.029887    0.400137
  GOTERM_CC_FAT   GO:0043233\~organelle lumen                               41      0.000671    0.049713    0.894362
  GOTERM_CC_FAT   GO:0043232\~intracellular nonmembrane-bounded organelle   53      0.000793    0.047075    1.056321
  GOTERM_CC_FAT   GO:0043228\~nonmembrane-bounded organelle                 53      0.000793    0.047075    1.056321
  GOTERM_CC_FAT   GO:0005793\~ER--Golgi intermediate compartment            5       0.00204     0.098288    2.697165
  GOTERM_CC_FAT   GO:0000267\~cell fraction                                 27      0.002078    0.086396    2.747502
  GOTERM_CC_FAT   GO:0005624\~membrane fraction                             22      0.002295    0.083602    3.029516
  GOTERM_CC_FAT   GO:0005875\~microtubule-associated complex                7       0.002312    0.075206    3.05179
  GOTERM_MF_FAT   GO:0046983\~protein dimerization activity                 21      0.000154    0.061492    0.215993
  GOTERM_MF_FAT   GO:0001882\~nucleoside binding                            43      0.000155    0.031399    0.217151
  GOTERM_MF_FAT   GO:0001883\~purine nucleoside binding                     42      0.000274    0.036878    0.383329
  GOTERM_MF_FAT   GO:0000166\~nucleotide binding                            53      0.000428    0.043003    0.597241
  GOTERM_MF_FAT   GO:0032553\~ribonucleotide binding                        45      0.000667    0.053362    0.929846
  GOTERM_MF_FAT   GO:0032555\~purine ribonucleotide binding                 45      0.000667    0.053362    0.929846
  GOTERM_MF_FAT   GO:0017076\~purine nucleotide binding                     46      0.000898    0.059685    1.25016
  GOTERM_MF_FAT   GO:0019003\~GDP binding                                   4       0.001858    0.103456    2.570935
  GOTERM_MF_FAT   GO:0032559\~adenyl ribonucleotide binding                 37      0.002135    0.104001    2.948878
  GOTERM_MF_FAT   GO:0030554\~adenyl nucleotide binding                     38      0.00282     0.120983    3.87696
  KEGG_PATHWAY    hsa04150:mTOR signaling pathway                           6       0.001995    0.195612    2.227286
  KEGG_PATHWAY    hsa05200:Pathways in cancer                               13      0.011181    0.458169    11.91115
  KEGG_PATHWAY    hsa04010:MAPK signaling pathway                           11      0.017441    0.472326    18.00035
  KEGG_PATHWAY    hsa04110:Cell cycle                                       7       0.021605    0.44854     21.83569
  KEGG_PATHWAY    hsa05218:Melanoma                                         5       0.035037    0.540452    33.12075
  KEGG_PATHWAY    hsa05219:Bladder cancer                                   4       0.036427    0.490394    34.19945
  KEGG_PATHWAY    hsa05212:PC                                               5       0.036617    0.440598    34.34575

**Abbreviations:** FDR, false discovery rate; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PC, pancreatic cancer.

[^1]: These authors contributed equally to this work
